Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valsartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 13/20 | 0.72 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valsartan SCHEMBL2328 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2542 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL29406387 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL157179 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL1560689 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408288 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408289 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21121526 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21121527 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL20527991 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4321157-A2 | NEW USE OF A COMBINATION OF AN ANGIOTENSIN RECEPTOR BLOCKER (ARB) WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR (NEPI) | Novartis AG (CH) | 2024-02-14 | — | — | EP | claimed |
| EP-3626270-B1 | TREATMENT OF CARDIOVASCULAR DISEASES | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | claimed |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2023-05-09 | — | — | US | claimed |
| US-20220331282-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | NOVARTIS PHARMACECUTICALS CORPORATION | 2022-10-20 | — | — | US | claimed |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-08-18 | — | — | US | claimed |
| US-20220133694-A1 | PHARMACEUTICAL USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-05-05 | — | — | US | claimed |
| US-20210361610-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2021-11-25 | — | — | US | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| US-20210077461-A1 | NEW USE | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | claimed |
| EP-3685833-A1 | COMPOUND COMPRISING AN ARB AND A NEPI | Novartis AG (CH) | 2020-07-29 | — | — | EP | claimed |
| EP-1393722-A2 | Use of angiotensin II subtype 1 (AT1) antagonists for the manufacture of a medicament in the treatment of premenstrual syndrome | DePadova, Anthony S. (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2003089417-A1 | NOVEL CRYSTALLINE FORMS OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2’-(1H-TETRAZOL-5-YL-)- BIPHENYL-4-YL METHYL] AMINE (VALSARTAN) | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-10-30 | — | — | WO | claimed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | claimed |
| EP-0759754-A4 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 2000-07-05 | — | — | EP | claimed |
| US-5753651-A | Use of AT1 antagonist such as irbesartan or candesartan cilexetil, among others; premenstrual syndrome (PMS) | DEPADOVA ANTHONY S (US) | 1998-05-19 | — | — | US | claimed |
| EP-0759754-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DePadova, Anthony S. (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | claimed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133694-A1 | PHARMACEUTICAL USE | TNNT2, TNNI3, NPPA | AGTR1 1236/4885LTB4R2 1417/4885ABCB11 14/4885 |
| US-20210361610-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 4/4885LTB4R2 1393/4885ABCB11 1638/4885 |
| US-20220331282-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | MME, DNPEP, AGTR1 | AGTR1 3/4885LTB4R2 2298/4885ABCB11 2470/4885 |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | MME, DNPEP, AGTR1 | AGTR1 3/4885LTB4R2 2312/4885ABCB11 1883/4885 |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | MME, DNPEP, AGTR1 | AGTR1 3/4885LTB4R2 2298/4885ABCB11 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.